Immunohistochemical localization of c-erbB-2 in human breast carcinomas

Gusterson, Barry A.; Gullick, William J.; Venter, D. J.; Powles, Trevor J.; Elliott, C.J.; Ashley, S.; Tidy, Alwynne; Harrison, S.

doi:10.1016/0890-8508(87)90019-3

Cited by 55 publications

(44 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Eighteen of 93 patients with gastric cancer (19%) had HER-2/neu overexpression, which was in line with previous reports. 10,19,22,23 The frequency of HER-2/neu overexpression in the carcinoma tissue of HLA-A2-positive and negative patients was almost equal at 20% and 19%, respectively. Moreover, there were no significant differences in the frequency of HER-2/neu status related to HLA-A11, A24, A26, B51 or Cw3 loci.…”

Section: Frequency Of Hla Haplotype Related To Her-2/neu Overexpressionmentioning

confidence: 96%

“…When the cell membranes of the carcinoma were stained, the patient was considered positive for overexpression of HER-2/neu, irrespective of the percentage of stained cells, as described previously. 19 To evaluate the infiltrating grade of TILs, the sections were incubated with anti-CD3 MAb (Dakopatts, Copenhagen, Denmark) and staining was performed using the LSAB technique described above. The grade of TILs was scored as low, moderate or high by 2 independent observers (K.K and A.T).…”

Section: Immunohistochemistrymentioning

confidence: 99%

“…19 It has been reported that FISH analysis is a more accurate tool than immunohistochemistry. 10 Thus, further study with the other methods for evaluation of HER-2/neu are needed, to perform more accurate estimation of percentages of candidates for HER-2/neubased immunotherapy.…”

Section: Relationship Between Clinicopathological Features and Hla Hamentioning

confidence: 99%

See 2 more Smart Citations

Frequencies of HER‐2/neu overexpression relating to HLA haplotype in patients with gastric cancer

Kono

Takahashi

Amemiya

et al. 2001

Intl Journal of Cancer

View full text Add to dashboard Cite

We have identified that HER-2/neu-derived peptides are naturally processed as tumor rejection antigens recognized by tumor-specific, HLA-A2-restricted cytotoxic T lymphocytes in gastric cancer. To evaluate candidates for immunotherapy using HER-2/neu-derived, HLA-A2-restricted peptides, we examined the frequency of HLA-A2 relating to HER-2/neu overexpression or the infiltrating grade of tumorinfiltrating lymphocytes (TILs) in Japanese patients with gastric cancer. HER-2/neu-overexpressing tumors detected by immunohistochemistry amounted to 19% of primary gastric cancers and HLA-A2-positive patients with gastric cancer were 31% of primary gastric-cancer cases. Finally, gastriccancer patients with both HLA-A2-positive and HER-2/neuoverexpressing tumors amounted to 6.6% of these cases. There was no significant difference in the infiltrating grade of TILs between gastric cancers overexpressing HER-2/neu and those that did not. Gastric cancer is 1 of the most common cancers occurring in Japan today. The control of gastric cancer at advanced stages still remains difficult, despite various treatments such as gastrectomy with extensive lymphadenectomy 1 and surgery combined with chemotherapy. 2 We and others reported that MHC class I-restricted cytotoxic-T lymphocytes (CTLs) from gastric-cancer patients can react specifically against autologous tumor cells. [3][4][5][6] Adoptive immunotherapy based on gastric cancer-specific CTLs, or vaccinations based on the MHC class I-associated tumor antigens that they recognize, represent alternative therapeutic approaches. The presence of tumor-associated antigens recognized by gastric-cancer-specific CTLs restricted by HLA-A31 6 or HLA-A2.1 molecules 4 has been demonstrated, although the nature of these antigens has not been defined. Moreover, we have identified that HER-2/neu-derived peptides are naturally processed as tumorassociated antigens recognized by tumor-specific, HLA-A2-restricted CTLs in gastric cancer. 7 Thus, HER-2/neu-derived peptides may be considered as candidates for tumor-specific immunotherapy such as tumor vaccination in patients with gastric cancer.The HER-2/neu protooncogene encodes a 185-kDa transmembrane glycoprotein with tyrosine-specific kinase activity. 8 The HER-2/neu protooncogene is amplified and overexpressed in approximately 30% of human ovarian and breast tumors 9 and in 20% of gastric cancers. 10 HLA-A2-restricted CTL epitopes derived from HER2/neu recognized by ovarian-11,12 and breast-13 cancerspecific CTLs have previously been defined, in addition to those specific for gastric cancer. The identification of several new HLA-A2-restricted CTL epitopes from HER-2/neu that can activate CTLs from healthy donors and patients with advanced ovarian carcinoma has also been reported. 14,15 These results indicate that HER-2/neu-derived peptides could be broad targets for immunotherapy against these types of cancers. It is important to evaluate candidates for tumor vaccination with HER-2/neu-derived peptides in patients with gastric cancer. Because it has...

show abstract

Section: Frequency Of Hla Haplotype Related To Her-2/neu Overexpressionmentioning

confidence: 96%

Section: Immunohistochemistrymentioning

confidence: 99%

See 1 more Smart Citation

Frequencies of HER‐2/neu overexpression relating to HLA haplotype in patients with gastric cancer

Kono

Takahashi

Amemiya

et al. 2001

Intl Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…Gene amplification has been shown to be closely associated with immunohistochemical assessment of the gene product in both frozen and paraffin embedded material (Venter et al, 1987;van de Vijver, 1988). A recent study by Gusterson et al (1988) indicates that the best association is with membrane staining by the polyclonal antibody 21N raised to the predicted amino acid sequence from residues 1243-1255 of the open reading frame of c-erbB-2. This immunohistochemical technique allows relatively simple retrospective analysis of archival material.…”

mentioning

confidence: 99%

An immunohistochemical evaluation of c-erbB-2 expression in human breast carcinoma

Barnes

Lammie²,

Millis³

et al. 1988

Br J Cancer

198

View full text Add to dashboard Cite

“…This reagent has been well characterised and widely used for immunohistochemical detection of c-erbB-2 in tissue sections (Gusterson et al, 1988). To detect EGF receptor immunoreactivity in frozen and paraffin sections an affinity-purified preparation of the rabbit antibody 12E (raised against a synthetic peptide representing residues 1059 to 1072 in the cytoplasmic domain of EGF receptor, Gullick et al, 1985) was used at a concentration of 4 gg ml-', as well as an affinity-purified preparation of the rabbit antibody 14E (raised against a synthetic peptide of residues 1164 to 1176 of EGF receptor, Gullick et al, 1985) (Falck & Gullick, 1989).…”

mentioning

confidence: 99%

Amplification and overexpression of the EGF receptor and c-erbB-2 proto-oncogenes in human stomach cancer

Lemoine

Jain²,

Silvestre³

et al. 1991

Br J Cancer

148

View full text Add to dashboard Cite

show abstract

Immunohistochemical localization of c-erbB-2 in human breast carcinomas

Cited by 55 publications

References 13 publications

Frequencies of HER‐2/neu overexpression relating to HLA haplotype in patients with gastric cancer

Frequencies of HER‐2/neu overexpression relating to HLA haplotype in patients with gastric cancer

An immunohistochemical evaluation of c-erbB-2 expression in human breast carcinoma

Amplification and overexpression of the EGF receptor and c-erbB-2 proto-oncogenes in human stomach cancer

Contact Info

Product

Resources

About